Phreesia Inc. (NYSE:PHR) Relative Strength Index (RSI) is 54.29, with weekly volatility at 4.00% and ATR at 2.02. The PHR stock’s 52-week price range has touched low of $26.20 and a $81.59 high. Intraday shares traded counted 0.45 million, which was 4.52% higher than its 30-day average trading volume of 474.38K. Its shares traded higher over the last trading session, gaining 2.01% on 05/27/21. The shares fell to a low of $47.89 before closing at $49.21. PHR’s previous close was $48.24 while the outstanding shares total 44.51M.
Investors have identified the Health Information Services company Phreesia Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.44 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Phreesia Inc. (PHR) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 272.27 million total, with 54.99 million as their total liabilities.
PHR were able to record -15.69 million as free cash flow during the 09/08/2021 quarter of the year, this saw their quarterly net cash flow reduce by 128.47 million. In cash movements, the company had a total of 2.89 million as operating cash flow.
Potential earnings growth for Phreesia Inc. (PHR)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 09/08/2021 quarter of the year, Phreesia Inc. recorded a total of 41.81 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 21.51% coming in sequential stages and their sales for the 09/08/2021 quarter increasing by 8.0%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 14.78 million trying to sell their products during the last quarter, with the result yielding a gross income of 27.02 million. This allows shareholders to hold on to 44.51M with the recently reported earning now reading -0.18 cents per share. This is a figure that compared to analyst’s prediction for their 09/08/2021 (-0.18 cents a share).
Having a look at the company’s valuation, the company is expected to record -0.57 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on PHR sounds very interesting.
Is the stock of PHR attractive?
In related news, Director, Munson Gillian sold 1,777 shares of the company’s stock in a transaction that recorded on May 12. The sale was performed at an average price of 44.43, for a total value of 78,953. As the sale deal closes, the See Remarks, Davidoff Michael J. now sold 2,134 shares of the company’s stock, valued at 107,784. Also, Director, CAHILL EDWARD L sold 15,000 shares of the company’s stock in a deal that was recorded on Apr 01. The shares were price at an average price of 54.94 per share, with a total market value of 824,115. Following this completion of acquisition, the SVP, Life Sciences, Linetsky David now holds 1,578 shares of the company’s stock, valued at 94,224. In the last 6 months, insiders have changed their ownership in shares of company stock by 5.30%.
10 out of 14 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Phreesia Inc.. 0 analysts has assigned a Sell rating on the PHR stock. The 12-month mean consensus price target for the company’s shares has been set at $64.83.